Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 13, 2025

FITC anti-human CD107a (LAMP-1)

RRID:AB_1186036
Type: Antibody

Proper Citation

(BioLegend Cat# 328606, RRID:AB_1186036)

Antibody Information

URL: http://antibodyregistry.org/AB_1186036

Proper Citation: (BioLegend Cat# 328606, RRID:AB_1186036)

Target Antigen: CD107a

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: FITC anti-human CD107a (LAMP-1)

Description: This monoclonal targets CD107a

Target Organism: human

Clone ID: Clone H4A3

Antibody ID: AB_1186036

Vendor: BioLegend

Catalog Number: 328606

Alternative Catalog Numbers: 328605

Record Creation Time: 20231110T053819+0000

Record Last Update: 20241115T123409+0000

Ratings and Alerts

No rating or validation information has been found for FITC anti-human CD107a (LAMP-1).

No alerts have been found for FITC anti-human CD107a (LAMP-1).

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Wang Y, et al. (2024) Venetoclax acts as an immunometabolic modulator to potentiate adoptive NK cell immunotherapy against leukemia. Cell reports. Medicine, 5(6), 101580.

Schmit MM, et al. (2024) A critical threshold of MCM10 is required to maintain genome stability during differentiation of induced pluripotent stem cells into natural killer cells. Open biology, 14(1), 230407.

Hofman T, et al. (2024) IFN? mediates the resistance of tumor cells to distinct NK cell subsets. Journal for immunotherapy of cancer, 12(7).

Felices M, et al. (2023) Reverse Translation Identifies the Synergistic Role of Immune Checkpoint Blockade and IL15 to Enhance Immunotherapy of Ovarian Cancer. Cancer immunology research, 11(5), 674.

Nelde A, et al. (2023) Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells. Blood cancer discovery, 4(6), 468.

Tobin RP, et al. (2023) Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(7), 1209.

Bauer J, et al. (2022) The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma. Nature communications, 13(1), 6401.

van der Ploeg K, et al. (2022) TNF-?+ CD4+ T cells dominate the SARS-CoV-2 specific T cell response in COVID-19 outpatients and are associated with durable antibodies. Cell reports. Medicine, 3(6), 100640.

Yen M, et al. (2022) Facile discovery of surrogate cytokine agonists. Cell, 185(8), 1414.

Maringer Y, et al. (2022) Durable spike-specific T cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccination. Science immunology, 7(78), eadd3899.

Bilich T, et al. (2021) T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals. Science translational medicine, 13(590).

Bilich T, et al. (2021) Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer. Cancer discovery, 11(8), 1982.

Ni J, et al. (2020) Single-Cell RNA Sequencing of Tumor-Infiltrating NK Cells Reveals that Inhibition of Transcription Factor HIF-1? Unleashes NK Cell Activity. Immunity, 52(6), 1075.

Bennstein SB, et al. (2020) Umbilical cord blood-derived ILC1-like cells constitute a novel precursor for mature KIR+NKG2A- NK cells. eLife, 9.

Xu H, et al. (2019) Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility. Cell stem cell, 24(4), 566.